Alopexx

Alopexx, Inc. is a clinical-stage, infectious disease-focused biotechnology company that recently made major moves to enter the public markets after a long, delayed planning phase dating back to 2022.

Unlike the high-revenue tech profiles of Lime or Bending Spoons, Alopexx operates on a traditional, high-risk preclinical/clinical biotech model, meaning it currently generates zero revenue and relies entirely on external funding to advance its pipeline.

🚨 Recent IPO Details & Terms (June 2026 Update)

Following several years of waiting, Alopexx officially filed updated paperwork with the SEC to aggressively move its public offering forward.

• Ticker Symbol: ALPX

• Target Exchange: NYSE American

• IPO Offering Size: $33 Million (The company significantly upsized its target from previous 2024 and 2025 filings which aimed for much lower amounts between $5M and $10M).

• Shares Offered: 3 million shares of common stock.

• Expected Price Range: $10.00 to $12.00 per share.

• Projected Valuation: At the $11.00 midpoint, the company’s fully diluted market capitalization is estimated to be roughly $102 Million.

• Sole Bookrunner: ThinkEquity

• Ownership Structure: CEO Daniel Vlock, M.D., is slated to retain a 56.3% stake in the outstanding common stock post-IPO, designating Alopexx as a “controlled company” under exchange guidelines.

📊 Company Fundamentals & Financial Status

Biotech companies at this stage have highly precarious balance sheets because their primary focus is pouring capital into drug development before experiencing any product sales.

• Revenue: $0. Alopexx does not have any commercially approved products and has zero active revenue streams.

• Critical Cash Crunch: Prior to the upsized IPO push, filings revealed the company was in extreme need of capital, operating with just $40,000 left in the bank.

• Operational Setup: Reflecting its lean nature, the company’s SEC filings explicitly noted they do not intend to have any full-time employees prior to the completion of the IPO, using contract research organizations (CROs) and consulting executives instead.

🧪 Scientific Pipeline & Core Assets

The capital raised from the public market is specifically earmarked to fund human trials for its key candidates. Both therapeutics target poly N-acetyl glucosamine (PNAG), a surface carbohydrate found on over 75 different types of pathogens (including severe, antimicrobial-resistant strains).

1. F598 (Monoclonal Antibody):

   • Status: Completed Phase 1 and a pilot Phase 2 trial, proving to be well-tolerated.

   • The Strategy: A single infusion is designed to provide immediate pathogen protection for 2 to 3 months. Alopexx plans to allocate roughly $9 Million of its IPO proceeds to run a proof-of-concept study specifically targeting intensive care unit (ICU) patients to prevent hospital-acquired infections. Historical Note: This asset was originally licensed to Sanofi back in 2009 under a $375 million deal before Sanofi ran into enrollment issues and walked away.

2. AV0328 (Synthetic Vaccine):

   • Status: Completed a Phase 1 trial.

   • The Strategy: It induces antibodies to proactively kill PNAG-expressing bacteria and fungi. Alopexx plans to spend roughly $6 Million of the IPO capital on a Phase 2 proof-of-concept trial. They view it as a major future complement to established pneumococcal vaccines like Prevnar.

Neurological Potential: Interestingly, Alopexx has also flagged that because PNAG-containing microbial fragments are linked to chronic brain inflammation, both of these therapeutics could eventually be studied for neurological conditions like Alzheimer’s Disease and Traumatic Brain Injury (TBI).